Next-generation sequencing (NGS) has revolutionized myriad fields, including the discovery and development of therapeutic antibodies. By enabling high-throughput sequencing of entire B cell repertoires, NGS offers unprecedented insights into the diversity and dynamics of antibody responses. This article delves into the use of NGS technology in the discovery and development of therapeutic antibodies.
The foundation of therapeutic antibody discovery lies in the B cells, which produce a vast array of antibodies with different specificities and affinities. NGS allows researchers to sequence the entire repertoire of B cells from an individual, providing a comprehensive view of the immune response. This includes both the heavy and light chain variable regions, which are essential for antigen recognition and binding.
By comparing B cell repertoires before and after antigen exposure, researchers can identify antigen-specific antibodies that may serve as potential therapeutics. Additionally, longitudinal sampling and sequencing can track the evolution of antibody responses, shedding light on processes such as affinity maturation and clonal expansion.
NGS has played a pivotal role in the discovery of therapeutic antibodies against infectious diseases. For instance, in the fight against COVID-19, NGS was used to sequence the B cell repertoires of convalescent patients, leading to the identification of potent neutralizing antibodies against SARS-CoV-2. These antibodies are being developed as therapeutics and prophylactics against COVID-19.
Beyond discovery, NGS also aids in the engineering and optimization of therapeutic antibodies. By sequencing libraries of antibody variants, researchers can assess the effects of sequence alterations on antibody properties, such as stability, affinity, and specificity. This high-throughput approach accelerates the process of antibody optimization, reducing the time and cost of therapeutic antibody development.
NGS of B cell repertoires can also contribute to the development of personalized therapies and biomarkers. By comparing the B cell repertoires of responders and non-responders to a particular treatment, researchers can identify antibody signatures associated with therapeutic response. These signatures could serve as predictive biomarkers, guiding the selection of appropriate therapies for individual patients.
Next-generation sequencing has brought about a new era of innovation in therapeutic antibody discovery and development. By providing a high-resolution view of B cell repertoires, NGS enables the identification of novel therapeutic antibodies, the optimization of antibody properties, and the discovery of predictive biomarkers. As NGS technologies continue to advance, we can expect to see even more groundbreaking contributions to the field of therapeutic antibodies.